Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is
better for treating stroke patients and if TNK offers an advantage over currently available
treatment with tissue plasminogen activator (tPA).
Phase:
Phase 2
Details
Lead Sponsor:
University of Virginia
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)